Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma
暂无分享,去创建一个
[1] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Hendrix,et al. Nodal signaling promotes a tumorigenic phenotype in human breast cancer. , 2014, Seminars in cancer biology.
[3] Antoni Ribas,et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.
[4] F. Wang,et al. Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells. , 2014, Cancer research.
[5] L. Kwong,et al. Targeted therapy for melanoma: rational combinatorial approaches , 2014, Oncogene.
[6] L. Tentori,et al. Challenging resistance mechanisms to therapies for metastatic melanoma. , 2013, Trends in pharmacological sciences.
[7] R. Sullivan,et al. The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be , 2013, Clinical Cancer Research.
[8] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[9] R. Sullivan,et al. Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.
[10] L. Postovit,et al. Nodal signalling in embryogenesis and tumourigenesis. , 2013, The international journal of biochemistry & cell biology.
[11] D. Corbeil,et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges , 2013, The Journal of pathology.
[12] D. Hess,et al. Nodal promotes invasive phenotypes via a Mitogen Activated Protein Kinase-dependent pathway , 2013, Oncogene.
[13] G. Belbin,et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens , 2012, Cell Death and Disease.
[14] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[15] V. A. Flørenes,et al. Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma , 2012, PloS one.
[16] Raha Abdul Rahim,et al. Development of Multicellular Tumor Spheroid (MCTS) Culture from Breast Cancer Cell and a High Throughput Screening Method Using the MTT Assay , 2012, PloS one.
[17] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[18] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[19] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[20] J. Annereau,et al. Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells , 2012, PloS one.
[21] M. Hendrix,et al. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer , 2012, Breast Cancer Research.
[22] Jorge S Reis-Filho,et al. Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.
[23] A. Califano,et al. Regulation of extra-embryonic endoderm stem cell differentiation by Nodal and Cripto signaling , 2011, Development.
[24] M. Hendrix,et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells , 2011, The Prostate.
[25] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[26] M. Hendrix,et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. , 2010, Cancer research.
[27] Sandeep Singh,et al. Rb–Raf-1 Interaction Disruptor RRD-251 Induces Apoptosis in Metastatic Melanoma Cells and Synergizes with Dacarbazine , 2010, Molecular Cancer Therapeutics.
[28] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[29] D. Khayat,et al. Treatment for metastatic malignant melanoma: old drugs and new strategies. , 2010, Critical reviews in oncology/hematology.
[30] Q. Zhan,et al. The embryonic morphogen, Nodal, is associated with channel‐like structures in human malignant melanoma xenografts , 2010, Journal of cutaneous pathology.
[31] M. Hendrix,et al. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. , 2009, Epigenomics.
[32] M. Lackmann,et al. Expression of nodal signalling components in cycling human endometrium and in endometrial cancer , 2009, Reproductive biology and endocrinology : RB&E.
[33] S. Morrison,et al. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.
[34] M. Hendrix,et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells , 2008, Proceedings of the National Academy of Sciences.
[35] Mohamed H. Sayegh,et al. Identification of cells initiating human melanomas , 2008, Nature.
[36] P. Valent,et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. , 2007, The Journal of investigative dermatology.
[37] M. Shen. Nodal signaling: developmental roles and regulation , 2007, Development.
[38] V. Sondak,et al. Chemotherapy for metastatic melanoma , 2007, Cancer.
[39] Juergen Friedrich,et al. Experimental anti-tumor therapy in 3-D: Spheroids – old hat or new challenge? , 2007, International journal of radiation biology.
[40] M. Hendrix,et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.
[41] R. Pedersen,et al. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. , 2004, Developmental biology.
[42] J. Kirkwood,et al. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.
[43] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[44] F. Cognetti,et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. , 2000, Journal of experimental & clinical cancer research : CR.
[45] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[47] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[48] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[49] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[50] M. Hendrix,et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. , 2009, Expert review of dermatology.
[51] A. Schier. Nodal morphogens. , 2009, Cold Spring Harbor perspectives in biology.